Sana Biotechnology (NASDAQ:SANA) Upgraded by TD Cowen to “Strong-Buy” Rating

TD Cowen upgraded shares of Sana Biotechnology (NASDAQ:SANA) to a strong-buy rating in a research note published on Monday,Zacks.com reports.

Several other equities analysts have also issued reports on the company. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Rodman & Renshaw initiated coverage on shares of Sana Biotechnology in a report on Monday, May 11th. They issued a “buy” rating and a $16.00 price target on the stock. Bank of America cut their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, August 14th. Finally, Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.33.

Sana Biotechnology Stock Performance

Shares of NASDAQ SANA opened at $3.78 on Monday. The stock has a 50 day moving average price of $3.49 and a 200 day moving average price of $3.41. The stock has a market capitalization of $1.13 billion, a PE ratio of -4.97 and a beta of 2.16. Sana Biotechnology has a 52 week low of $2.61 and a 52 week high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02. As a group, research analysts forecast that Sana Biotechnology will post -0.72 EPS for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Several hedge funds have recently bought and sold shares of the business. Rockefeller Capital Management L.P. grew its position in Sana Biotechnology by 74.3% during the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after purchasing an additional 4,088 shares during the last quarter. LRI Investments LLC bought a new position in Sana Biotechnology in the fourth quarter worth approximately $41,000. Walleye Capital LLC bought a new stake in Sana Biotechnology during the second quarter valued at about $35,000. Jacobi Capital Management LLC bought a new position in shares of Sana Biotechnology during the 4th quarter valued at approximately $41,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Sana Biotechnology in the third quarter worth $36,000. Institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.